NCT00460031 2020-07-24
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Case Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
4 trialsNCT00942578 2018-10-11
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00654186 2014-03-28
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Oncology Specialists, S.C.
Phase 2 Completed
NCT00179738 2005-11-23
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
Celgene
Phase 2 Terminated